Month: April 2024

Availability of the 2023 Universal Registration Document Bagneux, 30 April 2024, Quadient (Euronext Paris: QDT) announces that it has filed its 2023 Universal Registration Document, in xHTML format, with the French Financial Markets Authority (Autorité des marchés financiers or “AMF”), on 29 April 2024, under the reference number D.24-0365. The 2023 Universal Registration Document notably includes:The Annual Financial Report, comprising the parent company financial statements, the consolidated financial statements, the management report and the related statutory auditors’ reports; The report on corporate governance; The non-financial performance statement; The information related to fees paid to the statutory auditors; The required information in relation to the share repurchase program.Quadient’s 2023 Universal Registration Document...

30 April 2024, 18:15 CET The Annual General Meeting (‘General Meeting’) of shareholders of ArcelorMittal held today in Luxembourg approved all resolutions by a strong majority. 78.47% of the voting rights were represented at the General Meeting. The results of the votes will be posted shortly on www.arcelormittal.com under ‘Investors – Equity investors – Shareholders events – AGM – Annual General Meeting of shareholders, 30 April 2024’ where the full documentation regarding the General Meeting is available. In particular, the shareholders:Approved the distribution of a dividend of US$0.50 per share;Re-elected Mrs. Karyn Ovelmen and Mr. Clarissa Lins as directors of ArcelorMittal, for a term of three years each.ENDS About ArcelorMittal ArcelorMittal is one of the world’s leading integrated steel and mining companies with a presence...

April 30, 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa’s Licensor Emtora to Announce Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis to be Presented at Prestigious 2024 Digestive Disease Week Annual Meeting Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, is pleased to announce that’s its licensor Emtora Biosciences has announced that results of a Phase 2 clinical trial of eRapa in Familial Adenomatous Polyposis (“FAP”) are to be presented at the prestigious 2024 Digestive Disease Week annual meeting in Washington DC on May 18-21, 2024. Carol Burke, MD, the Principal Investigator, will present the six month data (NCT04230499)...

FOR IMMEDIATE RELEASE                         Annual General Meeting of 29 May 2024:Availability of the preparatory documents Clichy, France – April 30, 2024 – The Combined, Ordinary and Extraordinary, General Meeting of the shareholders of Société BIC will be held on Wednesday, May 29th, 2024, at 9:00 a.m. at the Cloud Business Center, 10 bis, rue du 4 Septembre, 75002 Paris. The notice of meeting (avis de reunion valant avis de convocation) was published at the French official legal announcement publication (BALO) on Friday, April 19th, 2024 (n°48, announcement 2400916) and the convening notice (avis de convocation) will be published in the Journal Spécial des Sociétés, a French newspaper of legal notice, on May 13th, 2024. The documents and information relating to this Annual General Meeting required under article R. 225-83 of...

Montrouge, 30 April 2024 CREDIT AGRICOLE S.A. ORDINARY AND EXTRAORDINARY GENERAL MEETING OF 22 MAY 2024 Publication of the Notice of Meeting – Opening of the vote –Procedures for making the preparatory documents available Crédit Agricole S.A. informs its shareholders that its Ordinary and Extraordinary General Meeting will be held on Wednesday, 22 May 2024 at 10.00 am in Orléans (45100), France, at Palais des Congrès CO’Met, 1 rue du Président Robert Schuman. A Notice of Meeting, including in particular the agenda and the draft resolutions, was published in the French bulletin of mandatory legal announcements (Bulletin des Annonces Légales Obligatoires) No. 38 of 27 March 2024. All of the matters relating to this General Meeting are made available to shareholders in accordance with the regulations and legislation in force. In particular:the...

  UAB „Orkela“ (hereinafter – the Company) publishes audited financial statements for the year. Ended 31 December 2023. The principal activity of the Company is real estate development and construction. The Company owns a land plot and building complex in Vilnius, at Vasario 16 st. 1. The Company is developing a lyceum and hotel complex next to the Church and Monastery of the Apostles St. Philip and James. The Company expects to complete the Project in 2024. Highlights of 2023On 2nd January 2023, the Company entered into a lease agreement with the main project tenant for 18,082 square meters of space in the Project, where Royal Russell branded school with student accommodation services will operate. In Q1 2023, the Company issued two tranches of bonds totaling 5 571 units (EUR 5 571 000 nominal value) out of its total bond issue with...

Not for distribution to United States news wire services or for dissemination in the United States TORONTO and HOUSTON, April 30, 2024 (GLOBE NEWSWIRE) — Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA) (MDNAF: OTCQB), a clinical-stage immunotherapy company focused on the development of engineered cytokines, announced today the closing of its previously announced CA$20 million investment by RA Capital Management, a multi-stage investment manager based in Boston, MA, by way of a non-brokered private placement (the “Offering”). Medicenna intends to use the net proceeds from the Offering for further development of its MDNA11 program, advancement of its preclinical programs and general corporate purposes. Pursuant to the terms of a subscription agreement entered into as of April 26, 2024 between the Company and...

Det skal oplyses, at der den 29. april i perioden 10:11 til 10:57 , er sket en fejl i beregningen af indre værdi for nedenstående afdelinger. Indre værdi for nedenstående afdelinger har i perioden været undervurderet.Afdelingsnavn ISIN Orderbookcode PåvirkningBæredygtig Defensiv KL DK0061671013 NBIBDKL -0,58%Bæredygtig Moderat KL DK0061671286 NBIBMKL -0,33%Defensiv KL DK0016188733 NBIDEKL -0,62%Moderat KL DK0016188816 NBIMOKL -0,35%Eventuel henvendelse vedrørende denne meddelelse kan rettes til NPA.PM@nykredit.dk eller JNA@nykredit.dk. Med venlig hilsen Nykredit Portefølje Administration A/S Tage Fabrin-Brasted